Fc Receptor Expression as a Prognostic Factor in Patients With Non-small-cell Lung Cancer

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The neonatal Fc receptor (FcRn) plays a crucial role in passive immunity and is implicated in cancer immunity.
• Non-small cell lung cancer (NSCLC) is a leading cause of cancer death, characterized by heterogeneity affecting prognosis.
• FcRn is expressed in the lungs, a primary site for lung cancer development.

Purpose of the Study:

• To investigate FcRn expression in NSCLC surgical specimens.
• To determine the correlation between FcRn expression and patient prognosis in NSCLC.

Main Methods:

• Immunohistochemistry was used to analyze FcRn expression in 140 NSCLC surgical specimens.
• Clinicopathological data and survival outcomes were correlated with FcRn expression.
• Statistical analysis included chi-squared tests and Kaplan-Meier survival analysis.

Main Results:

• FcRn-positive NSCLC patients showed significantly higher disease-free survival.
• A trend towards increased disease-specific survival was observed in FcRn-positive patients with tumor-node-metastasis stage I NSCLC.

Conclusions:

• FcRn down-regulation is associated with NSCLC progression.
• FcRn expression may serve as a prognostic biomarker in NSCLC.